Search

REVOLUTION Medicines Inc

Geschlossen

BrancheGesundheitswesen

205.1 -0.19

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

201.78

Max

208.05

Schlüsselkennzahlen

By Trading Economics

Einkommen

-644M

-1.1B

EPS

-2.34

Angestellte

883

EBITDA

-184M

-621M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+6.53% upside

Dividenden

By Acuity

Nächstes Ergebnis

4. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

5.6B

44B

Vorheriger Eröffnungskurs

205.29

Vorheriger Schlusskurs

205.1

Nachrichtenstimmung

By Acuity

65%

35%

283 / 340 Ranking in Healthcare

REVOLUTION Medicines Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Aug. 2026, 19:36 UTC

News

Revolution Medicines Inc is trading lower as broader geopolitical tensions and upcoming U.S. inflation reports weigh on market sentiment.

10. Aug. 2026, 23:51 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, maintaining a position above the 20-day moving average and near the one-month range's upper end.

7. Aug. 2026, 19:11 UTC

News

Revolution Medicines Inc shares are higher as the company plans a Phase 3 study and Wedbush raises its price target to $201 from $192.

6. Aug. 2026, 19:36 UTC

Social Media
News

Revolution Medicines Inc is trading higher as RBC Capital and Evercore ISI raise price targets, reflecting growing confidence in the company's clinical pipeline.

5. Aug. 2026, 23:02 UTC

Social Media
News

Revolution Medicines shares lower in after-market trading following a second-quarter loss of $644.4 million and an EPS of -$3.06, missing estimates.

4. Aug. 2026, 23:06 UTC

Revolution Medicines shares are lower in after-market trading, settling near Tuesday's close. The stock remains above its 20-day moving average.

3. Aug. 2026, 23:26 UTC

Revolution Medicines Inc shares are trading higher in after-market hours. Broader market sentiment is positive, influenced by declining oil prices and reduced inflation concerns.

31. Juli 2026, 20:06 UTC

Revolution Medicines Inc. shares are lower amid broader market volatility and rising U.S. Treasury yields, which have heightened inflation concerns and interest rate expectations.

30. Juli 2026, 22:41 UTC

Revolution Medicines Inc. shares are lower in after-market trading, declining since Thursday's close amid fluctuations in bond yields and Fed policy uncertainty.

29. Juli 2026, 17:02 UTC

Revolution Medicines Inc shares are lower, continuing a four-session decline with unusually high trading volume. The stock remains below its 20-day moving average.

28. Juli 2026, 19:02 UTC

Revolution Medicines Inc shares are lower today, continuing a decline since Monday amid negative broader market sentiment following significant drops in Asian markets.

27. Juli 2026, 20:06 UTC

Revolution Medicines Inc shares are lower amid broader market dynamics, including a decline in oil prices and falling Treasury yields ahead of the Federal Reserve meeting.

24. Juli 2026, 18:26 UTC

Social Media
News

Revolution Medicines shares are lower amid broader market sentiment, despite RJ's increased price target of $230 and positive FDA news on daraxonrasib.

22. Juli 2026, 18:26 UTC

Revolution Medicines Inc shares are higher today amid broader geopolitical tensions affecting market sentiment, despite no specific company news driving the movement.

21. Juli 2026, 17:16 UTC

Revolution Medicines Inc shares are higher today, reflecting gains since Monday amid supportive market conditions and positive sentiment from Asian markets and easing oil prices.

20. Juli 2026, 17:31 UTC

Social Media
News

Revolution Medicines Inc. shares are lower today despite upcoming catalysts and a projected revenue estimate of $13-15 billion by 2035. Trading volume is unusually high.

Peer-Vergleich

Kursveränderung

REVOLUTION Medicines Inc Prognose

Kursziel

By TipRanks

6.53% Vorteil

12-Monats-Prognose

Durchschnitt 220.48 USD  6.53%

Hoch 291 USD

Tief 151 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für REVOLUTION Medicines Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

19 ratings

18

Buy

1

Halten

0

Sell

Stimmung

By Acuity

283 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat